RetroSense Therapuetics Logowhite spacerGo to about RetroSenseGo to Investors and Partners pageGo to Product DevelopmentGo to Therapeutics AreasGo to Frequently Asked QuestionsGo to Contact Page
left image bandRight Image band
photoRetroSense Therapeutics develops game-changing gene therapy solutions to restore partial sight for certain eye diseases.
Management Team

Sean Ainsworth
CEO and Founder


Sean Ainsworth has twenty years of experience in pharmaceuticals and biotechnology. He has had deep involvement in the launch of two earlier startup companies, Compendia Bioscience, Inc. and GeneVivo, LLC where he assisted in developing business models, licensing technologies, building management teams, securing capital and first customers. Compendia BioScience was acquired by Life Technologies in October, 2012.

His experience also includes research at Medical Biology Institute (now Avanir Pharmaceuticals developers of Abreva, the leading cold sore medication) in San Diego, intellectual property at Koyama and Associates in Tokyo, international corporate development consulting at The Mattson Jack Group in St. Louis, MO.

In 2004 Mr. Ainsworth launched Ainsworth BioConsulting to provide licensing, strategic planning, and business planning services to the life science and entrepreneurial community. Mr. Ainsworth’s clients included large pharma, small biotechs, universities, CROs, and venture investment funds. He has worked with clients at all stages of development.

Mr. Ainsworth holds a BS in Microbiology from University of California, San Diego and an MBA in strategy and finance from Washington University in St. Louis.



(return to top of page)


Peter Francis, BSc(Hons), BM, MD, PhD, FRCOphth
Chief Medical Officer


Dr. Francis is an ophthalmologist clinician-scientist with expertise in ophthalmic genetics and retinal disease. Peter graduated from medical school in the UK and undertook residency in London, UK. He is fellowship trained in retina and genetics (Moorfields Eye Hospital, London, and Casey Eye Institute, USA). Dr Francis has held academic faculty positions at St Thomas’ Hospital, London and most recently, Casey Eye Institute, Portland, USA in which he has gained extensive experience of translational medicine and early phase human clinical trials for retinal disease. He has published over ninety peer-reviewed articles, together with more than one hundred presentations at national and international meetings on many aspects of retinal disease including gene identification, gene and stem cell therapy. Peter is a member of both the Macula the American Ophthalmological Societies. He has contributed chapters for several of prestigious textbooks including Duane’s Clinical Ophthalmology. He is the recipient of several awards including “best up-and-coming medical researcher in the United Kingdom 2002”.



(return to top of page)
 

Steven Bramer, PhD
Chief Development Officer


Dr. Steven Bramer has over 26 years of pharmaceutical/biotechnology industrial and academic experience. He has held positions in global companies where he contributed substantially to all stages of development for drugs, biologics, tissues, combination products, and devices. His experience covers a broad range of therapeutic areas, including ophthalmology, and he has dealt extensively with regulatory agencies in the US and abroad. He played an instrumental role in the submission of numerous INDs, NDAs, aNDAs, JNDAs, MAAs, BLAs, 510Ks, IDEs, and PMA submissions. Dr. Bramer has served in leadership roles throughout most of his career, leading departments, teams, and initiatives successfully. His business experience includes strategic planning, out-sourcing, contracts, in-licensing, out-licensing, co-development, and partnerships. He continues to stay affiliated with the academic community as an Associate Adjunct Professor at The Ohio State University. He has presented at major scientific meetings and is an author on numerous publications. Specialties include pharmacology, pharmacokinetics and pharmacodynamics, biopharmaceutics, metabolism, pharmacometrics, biostatistics, regulatory, and clinical operations.

Dr. Bramer is founder of a consulting company geared towards moving products from the bench and into the clinic. In addition to his other leadership roles, he also served as the Chief Drug Development Officer while working for the Foundation Fighting Blindness and its clinical arm, the National Neurovision Research Institute.

Dr. Bramer holds an AS degree in Biology from Delhi College, BS degree in Animal Science from Cornell University, and has completed a MS program in Pathology and a Ph.D. in Pharmaceutics from The Ohio State University.




(return to top of page)


Cam Gallagher
Chief Business Officer


Mr. Gallagher currently serves as Managing Director of Nerveda, LLC, a life science seed fund he founded in June 2009. Previously, from September 2007 until June 2009, Mr. Gallagher served as President and Chief Executive Officer of Nerveda, a privately held specialty pharmaceutical company.

Since October 2008, Mr. Gallagher has served as Chairman of the Board of Directors of DioGenix, a privately held molecular diagnostic company and he has served on the Board of Directors of Sorrento Therapeutics since September 2012. From December 2004 through June 2007, Mr. Gallagher served in various senior marketing positions at Verus Pharmaceuticals, a privately held specialty pharmaceutical company. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.Sc. in Business Administration from the Ohio University.



(return to top of page)